On June 12, 2019, the Canadian Agency for Drugs and Technologies in Health (CADTH) reported changes (effective July 1, 2019) to transition Cancer Drug Implementation Advisory Committee (CDIAC) functions to the CADTH pan-Canadian Oncology Drug Review (pCODR) review process. The purpose of the changes is to:
- “enhance the transparency of the pan-Canadian cancer drug review process”;
- “allow for greater stakeholder input into the development of a provisional algorithm for each new cancer drug or indication to indicate how the new therapy could be used compared to existing funded treatments; and to indicate the impact on the sequence of use for other existing funded therapies to better support jurisdictional decision-making for drug reimbursement”; and
- “streamline and reduce the duplication of administrative processes”.
The reported changes follow a period (beginning March 2019) of consultation with stakeholders.
Related Publications & Articles
-
New PMPRB Guidelines will not be implemented January 1, 2023
The Patented Medicine Prices Review Board (PMPRB) has advised that the new Guidelines will not be implemented on January 1, 2023, and that the Interim Guidance issued by the Board on August 18, 2022 w...Read More -
Ontario is the latest jurisdiction to implement a biosimilars transition policy
On December 20, 2022, Ontario announced it is implementing a biosimilars transition policy. Starting March 31, 2023, patients receiving coverage from the Ontario Drug Benefit plan for the following in...Read More -
Innovative Medicines Canada proposes framework for innovative agreements for drug reimbursement
Pharmaceutical manufacturers in Canada often enter into Product Listing Agreements (PLA), particularly with public payors, to facilitate their drug being reimbursed. It is common for PLAs to take the ...Read More